UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
Ella Day | September 18, 2025 | News story | Medical Communications, Research and Development | Dermatology, UCB, atopic dermatitis, clinical trial
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults with moderate-to-severe atopic dermatitis (AD). Findings from the phase 1/2a study were presented this week at the European Academy of Dermatology and Venereology Congress in Paris, France.
At week 12, 64.9% of patients receiving galvokimig achieved at least a 75% improvement in skin lesions, compared with 12.3% in the placebo group. Nearly half reached a 90% improvement, versus 3.5% for placebo. After 18 weeks, the most common treatment-emergent side effects included rhinitis, nasopharyngitis, headache, dizziness and throat pain.
Galvokimig is a multi-specific antibody therapy designed to target three inflammatory proteins implicated in the chronic inflammation of AD. By inhibiting both Th2 and Th17 pathways, researchers hope it can address the disease’s complex immune mechanisms and improve treatment outcomes.
Jonathan Silverberg, professor of dermatology at the George Washington University School of Medicine & Health Sciences, Washington, DC, US and co-author of the study, said: “The data indicates the potential of galvokimig to deliver clinically meaningful improvements in larger-scale clinical trials for patients with atopic dermatitis.”
UCB confirmed that a phase 2b trial is expected to begin by the end of 2025.
Atopic dermatitis affects between 2% and 10% of adults worldwide and is associated with significant impacts on quality of life.
Ella Day
18/9/25
This article featured in: October 2025 – The Pharmafile Brief
Related Content
Rare and severe epilepsies – current treatments and advance therapeutics
The current forms of immunotherapy, how T cell therapy works and what the future holds
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
